Related Experiment Video
Updated: Dec 11, 2025
06:46
Measurement of Tactile Allodynia in a Murine Model of Bacterial Prostatitis
Published on: January 16, 2013
16.2K
T2 Peptide Represents a Major Autoantigen Epitope in Experimental Autoimmune Prostatitis
Yuqian Liu1, Meng Tang1, Qin Zhang1
1Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, Jiangsu Province, China.
Inflammation
|August 23, 2020
Summary
Researchers identified T2 as a key factor in chronic prostatitis/chronic pelvic pain syndromes (CP/CPPS). Targeting T2 with antibodies significantly reduced pain and inflammation in an animal model, offering new insights into CP/CPPS etiology.
Area of Science:
- Urology
- Immunology
- Inflammation Research
Background:
- Chronic prostatitis/chronic pelvic pain syndromes (CP/CPPS) presents diagnostic and therapeutic challenges due to unknown causes and high recurrence rates.
- Understanding the underlying pathogenesis of CP/CPPS is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the role of T2 in the development of experimental autoimmune prostatitis (EAP) and its potential as a therapeutic target for CP/CPPS.
Main Methods:
- An EAP mouse model was established by immunizing C57BL/6 mice with prostate extracts.
- Pelvic pain, prostate inflammation (histopathology), and serum TNF-α levels were assessed.
- The effect of anti-T2 polyclonal antibodies on EAP symptoms was evaluated.
Main Results:
- Mice immunized with prostate extracts developed prostatitis, decreased pain thresholds, and elevated TNF-α levels.
- Administration of anti-T2 antibodies significantly alleviated EAP symptoms in the affected mice.
- These findings suggest T2 is a critical component in the EAP model.
Conclusions:
- T2 peptide may act as a major autoantigen epitope in EAP.
- Targeting T2 with antibodies shows promise for ameliorating CP/CPPS symptoms.
- This research provides a potential avenue for understanding and treating CP/CPPS.
